Table 2. Descriptive data for subjects in the study.
| Untreated group | Treated group | Control | |
|---|---|---|---|
| Number of subjects | 32 | 35 | 16 |
| Gender | All male | All male | All male |
| Age (mean ± SD) | 36.63 ± 8.05 | 36.34 ± 8.10 | 35.7 ± 10.23 |
| BMI(mean ± SD) | 22.31 ± 2.70 | 23.48 ± 2.54 | 22.83 ± 3.04 |
| Years diagnosed (mean ± SD) | 4.34 ± 2.8 | 4.97 ± 2.18 | / |
| Transmission, no. | |||
| Injection Drug Use | 11 | 4 | / |
| Heterosexual | 12 | 21 | / |
| Homosexual transmission | 4 | 4 | / |
| Drug and sexual | 5 | 6 | / |
| CD4 count (mean ± SD) | 352.66 ± 179.63 | 363.43 ± 185.28 | / |
| Plasma viral load (HIV-1 RNA copies/mL, mean ± SD) | 103838.50 ± 157786.55 | 314.95 ± 289.39 | / |
| HAART years (mean ± SD) | / | 2.49 ± 1.42 | / |
| Cytokines | |||
| IFN-γ(pg/mL, mean ± SD) | 8.172 ± 4.177 | 7.377 ± 2.295 | 10.788 ± 3.852 |
| IL-2(pg/mL, mean ± SD) | 0.408 ± 0.894 | 0.505 ± 1.134 | 3.310 ± 3.039 |
| IL-6(pg/mL, mean ± SD) | 2.576 ± 7.480 | 19.114 ± 9.725 | 18.690 ± 10.304 |
| IL-10(pg/mL, mean ± SD) | 0.214 ± 0.286 | 1.187 ± 2.692 | 1.272 ± 1.523 |
| IL-22(pg/mL, mean ± SD) | 0.997 ± 3.890 | 1.976 ± 3.470 | 12.524 ± 26.289 |
| TGF-β(pg/mL, mean ± SD) | 3653.136 ± 1491.749 | 2919.154 ± 1035.554 | 2147.174 ± 1104.937 |
| TNF-α(pg/mL, mean ± SD) | 2.164 ± 0.398 | 10.117 ± 12.494 | 9.413 ± 9.713 |
Abbreviations: BMI, body mass index; HAART, highly active antiretroviral therapy; SD, standard deviation.